Investors

The Column Group

The Column GroupThe Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. We will deploy our first fund of approximately $260M to build 8-10 disease-focused drug discovery companies, each with the potential to become a leader in their respective field(s). These companies will be strongly supported by the unique and complementary skill-sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, we will commit $20M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies.

5AM Ventures

5am Ventures5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors. Founded in 2002, 5AM Ventures has $685 million under management and is actively investing 5AM Ventures IV, a $250 million fund. 5AM’s investment professionals possess strong scientific, medical, operational, legal and finance expertise. Our complementary backgrounds provide us with a unique edge to find and shape life science portfolio companies. Our team employs a hands-on approach to company building and, in addition to being an early investor and contributing as board members, 5AM is often directly involved in setting company strategy, management recruiting, business development and fundraising, and we frequently take on short-term operating roles. The firm has offices in Menlo Park, California and Waltham, Massachusetts.

Orbimed

OrbiMedOrbiMed is a leading investment firm dedicated exclusively to the healthcare sector. With $7 billion in assets under management, OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles.

Third Rock Ventures

Third Rock VenturesThird Rock Ventures was founded in 2007 with the mission to launch transforming companies. We set out to build a different firm – a firm that was squarely focused on launching exceptional life science companies with passionate entrepreneurs, working in areas of disruptive science to make a difference in the lives of patients. In just three short years, and during a period of time when early stage investing has been in flux, we have successfully raised more than $800 million to accomplish this mission. We truly believe that nothing is impossible.